Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMH9O6V)

Drug Name
1-Cyclohexyl-3-phenethyl-urea Drug Info
Synonyms
N-cyclohexyl-N'-(2-phenylethyl)urea; 1-cyclohexyl-3-phenethylurea; CHEMBL193888; MLS000061067; 1-Cyclohexyl-3-phenethyl-urea; AC1LEVP0; AC1Q5P4E; Cambridge id 5402894; Oprea1_499442; SCHEMBL12196137; CHEBI:108334; MolPort-001-839-964; ZINC182146; HMS2444C08; HMS1582O21; 1-cyclohexyl-3-(2-phenylethyl)urea; 3-cyclohexyl-1-(2-phenylethyl)urea; BDBM50167058; AKOS001026537; MCULE-2992993146; SMR000069580; US8815951, 36; AB00084095-01; Z44585920
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
742677
ChEBI ID
CHEBI:108334
TTD Drug ID
DMH9O6V

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Soluble epoxide hydrolase (EPHX2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AR9281 DMJHA6Q Hypertension BA00-BA04 Phase 2 [2]
GSK2256294 DM7FN12 Chronic obstructive pulmonary disease CA22 Phase 1 [3]
13-n-Heptanamidotridec-8(Z)-enoic acid DM0LGWJ Discovery agent N.A. Investigative [4]
N-(naphthalen-1-yl)benzo[d]isoxazol-3-amine DM2CBNG Discovery agent N.A. Investigative [5]
1-adamantan-1-yl-3-(6-propyloxyhexyl)urea DMO1L3I Discovery agent N.A. Investigative [6]
N-adamantyl-N'-cyclohexylurea DMZ43N1 Discovery agent N.A. Investigative [2]
13-(N-Methyl-n-heptnamido)tridec-8(Z)-enoic acid DM689TH Discovery agent N.A. Investigative [4]
N-(3,3-Diphenyl-propyl)-isonicotinamide DMOXR4K Discovery agent N.A. Investigative [7]
1-Adamantan-1-yl-3-(3-hydroxy-phenyl)-urea DM8SEJP Discovery agent N.A. Investigative [8]
1-Cyclohexyl-3-(1-propionylpiperidin-4-yl)urea DMAZYCD Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Soluble epoxide hydrolase (EPHX2) TT7WVHI HYES_HUMAN Inhibitor [1]

References

1 Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9.
2 Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem. 2007 Aug 9;50(16):3825-40.
3 In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor. Prostaglandins Other Lipid Mediat. 2013 Jul-Aug;104-105:25-31.
4 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75.
5 A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5716-21.
6 1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic prope... J Med Chem. 2007 Oct 18;50(21):5217-26.
7 Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase. J Med Chem. 2009 Oct 8;52(19):5880-95.
8 Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9.
9 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, a... J Med Chem. 2010 Oct 14;53(19):7067-75.